Unknown

Dataset Information

0

Annexin A5 increases survival in murine sepsis model by inhibiting HMGB1-mediated pro-inflammation and coagulation.


ABSTRACT: The identification of HMGB1 as a late-mediator in sepsis has highlighted HMGB1 as a promising therapeutic target for sepsis treatment. Recent studies have revealed that annexin A5, a 35 kDa Ca2+-dependent phospholipid binding protein, exerts anti-inflammatory effect by inhibiting LPS binding to TLR4/MD2 complex. Annexin A5 administration has been shown to protect against endotoxin lethality even when the treatment was given after the early cytokine response, which prompted our group to suspect that annexin A5 may inhibit the binding of HMGB1, as well as endotoxin to TLR4. Here we suggest annexin A5 as a new inhibitor of HMGB1-mediated pro-inflammatory cytokine production and coagulation in sepsis. We first confirmed the inhibitory role of annexin A5 in LPS-induced production of pro-inflammatory cytokines both in vitro and in vivo. We observed that annexin A5 protects against tissue damage and organ dysfunction during endotoxemia in vivo. We then assessed the inhibiting role of annexin A5 in HMGB1/TLR4 interaction, and showed that annexin A5 treatment reduces HMGB1-mediated cytokines IL6 and TNF? both in vitro and in vivo. Finally, we confirmed that anticoagulant property of annexin A5 persists in various septic conditions including elevated HMGB1. Overall, we suggest annexin A5 as an alternative therapeutic approach for controlling HMGB1-mediated pro-inflammation and coagulation in patients with sepsis.

SUBMITTER: Park JH 

PROVIDER: S-EPMC5072405 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Annexin A5 increases survival in murine sepsis model by inhibiting HMGB1-mediated pro-inflammation and coagulation.

Park Jung Hwa JH   Jang Jong-Hwa JH   Choi Eun Jung EJ   Kim Young Seob YS   Lee Eun Ji EJ   Jung In Duk ID   Han Hee Dong HD   Wu T-C TC   Hung Chien-Fu CF   Kang Tae Heung TH   Park Yeong-Min YM  

Molecular medicine (Cambridge, Mass.) 20160706


The identification of HMGB1 as a late-mediator in sepsis has highlighted HMGB1 as a promising therapeutic target for sepsis treatment. Recent studies have revealed that annexin A5, a 35 kDa Ca<sup>2+</sup>-dependent phospholipid binding protein, exerts anti-inflammatory effect by inhibiting LPS binding to TLR4/MD2 complex. Annexin A5 administration has been shown to protect against endotoxin lethality even when the treatment was given after the early cytokine response, which prompted our group t  ...[more]

Similar Datasets

| S-EPMC3494014 | biostudies-literature
| S-EPMC3917105 | biostudies-literature
| S-EPMC3299293 | biostudies-literature
2023-12-31 | GSE225194 | GEO
| S-EPMC3893065 | biostudies-literature
| S-EPMC5554965 | biostudies-literature
2023-12-31 | GSE225192 | GEO
| S-EPMC6826004 | biostudies-literature
| S-EPMC7549025 | biostudies-literature
| S-EPMC3104517 | biostudies-literature